Yi-Chun Chien1,2, Ying-Hsiang Chou3,4, Wei-Hsun Wang5,6, John Chun-Hao Chen7, Wen-Shin Chang8, Chia-Wen Tsai8, DA-Tian Bau9,10, Jeng-Jong Hwang11,12. 1. Department of Medical Imaging and Radiological Sciences, I-Shou University, Jiaosu Village, Kaohsiung, Taiwan, R.O.C. 2. School of Medicine, I-Shou University, Jiaosu Village, Kaohsiung, Taiwan, R.O.C. 3. Department of Radiation Oncology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C. 4. Department of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 5. Department of Orthopedic Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 6. Department of Medical Imaging and Radiology, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan, R.O.C. 7. Department of Radiation Oncology, Mackay Memorial Hospital, New Taipei City, Taiwan, R.O.C. 8. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C. 9. Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C. jjhwang@ym.edu.tw johnjjhwang@gmail.com datian@mail.cmuh.org.tw artbau2@gmail.com. 10. Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C. 11. Department of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung, Taiwan, R.O.C. jjhwang@ym.edu.tw johnjjhwang@gmail.com datian@mail.cmuh.org.tw artbau2@gmail.com. 12. Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C.
Abstract
BACKGROUND/AIM: In precision therapy, liposomal encapsulated chemotherapeutic drugs have been developed to treat cancers by achieving higher drug accumulation in the tumor compared to normal tissues/organs. MATERIALS AND METHODS: We developed a novel chemoradiotherapeutic approach via nanoliposomes conjugated with vinorelbine (VNB) and 111In (111In-VNB-liposome) and examined their pharmacokinetics, biodistribution, maximum tolerance dose, and toxicity in a NOD/SCID mouse model. RESULTS: Pharmacokinetic results showed that the area under the curve (AUC) of PEGylated liposomes was about 17-fold higher than that of the free radioisotope. Tumor growth inhibition by 111In-VNB-liposome was significantly higher than that of the control (p<0.05). CONCLUSION: The tumors in NOD/SCID mice bearing HT-29/tk-luc xenografts were significantly suppressed by 111In-VNB-liposomes. The study proposed repeated treatments with a novel liposome-mediated radiochemotherapy and validation of therapeutic efficacy via imaging. Copyright
BACKGROUND/AIM: In precision therapy, liposomal encapsulated chemotherapeutic drugs have been developed to treat cancers by achieving higher drug accumulation in the tumor compared to normal tissues/organs. MATERIALS AND METHODS: We developed a novel chemoradiotherapeutic approach via nanoliposomes conjugated with vinorelbine (VNB) and 111In (111In-VNB-liposome) and examined their pharmacokinetics, biodistribution, maximum tolerance dose, and toxicity in a NOD/SCIDmouse model. RESULTS: Pharmacokinetic results showed that the area under the curve (AUC) of PEGylated liposomes was about 17-fold higher than that of the free radioisotope. Tumor growth inhibition by 111In-VNB-liposome was significantly higher than that of the control (p<0.05). CONCLUSION: The tumors in NOD/SCIDmice bearing HT-29/tk-luc xenografts were significantly suppressed by 111In-VNB-liposomes. The study proposed repeated treatments with a novel liposome-mediated radiochemotherapy and validation of therapeutic efficacy via imaging. Copyright
Authors: Mai Johnson; Breanne D W Karanikolas; Saul J Priceman; Russell Powell; Margaret E Black; Hsiao-Ming Wu; Johannes Czernin; Sung-Cheng Huang; Lily Wu Journal: J Nucl Med Date: 2009-04-16 Impact factor: 10.057
Authors: Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2016-06-02 Impact factor: 508.702